Home > Insider Trading > Filing (0001104659-13-086457)

Filing Details

Accession Number:: 0001104659-13-086457
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-11-21 20:01:26
Reporting Period:: 2013-11-19

Filing Date:: 2013-11-21
Accepted Time:: 2013-11-21 20:01:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
896262	Amedisys Inc	AMED	Services-Home Health Care Services (8082)	113131700

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1081714	R Henry Kravis	C/O Kohlberg Kravis Roberts &Amp; Co 9 West 57Th St New York NY 10019	No	No	Yes	No
1081715	R George Roberts	2800 Sand Hill Road Menlo Park CA 94025	No	No	Yes	No
1399770	Kohlberg Kravis Roberts & Co. L.p.	9 West 57Th Street Suite 4200 New York NY 10019	No	No	Yes	No
1404912	Kkr & Co. L.p.	9 West 57Th Street Suite 4200 New York NY 10019	No	No	Yes	No
1472692	Kkr Management Holdings Corp	9 West 57Th Street 41St Floor New York NY 10019	No	No	Yes	No
1472693	L.p. Holdings Management Kkr	9 West 57Th Street 41St Floor New York NY 10019	No	No	Yes	No
1472694	Kkr Management Llc	9 West 57Th Street 41St Floor New York NY 10019	No	No	Yes	No
1472695	Ltd Group Kkr	9 West 57Th Street 41St Floor New York NY 10019	No	No	Yes	No
1472696	L.p. Holdings Group Kkr	9 West 57Th Street 41St Floor New York NY 10019	No	No	Yes	No
1520692	Kkr Asset Management Llc	C/O Kkr Asset Management Llc 555 California Street, 50Th Floor San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-11-19	188,598	$14.43	4,599,691	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2013-11-20	156,917	$14.39	4,756,608	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2013-11-21	80,000	$14.77	4,836,608	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Footnotes

The price reported in Column 4 is a weighted average price. These shares of common stock, par value $0.001 per share ("Common Stock"), of Amedisys Inc. (the "Issuer") were purchased in multiple transactions ranging from$14.24 to $14.55, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (3) and (4).
In a Form 4 filed on October 21, 2013, the reporting persons reported a purchase of 2,700 shares of Common Stock on October 18, 2013. The correct number of shares purchased on that date is 2,678, and the totals reported herein reflect this adjustment.
The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions ranging from $14.20 to $14.50, inclusive.
The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions ranging from $14.60 to $14.85, inclusive.
Represents the aggregate number of shares of Common Stock held in client accounts for which KKR Asset Management LLC ("KAM") serves as an investment advisor.
Kohlberg Kravis Roberts & Co. L.P. is the holder of all of the outstanding equity interests in KAM. KKR Management Holdings L.P. is the general partner of Kohlberg Kravis Roberts & Co. L.P. and KKR Management Holdings Corp. is the general partner of KKR Management Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Management Holdings Corp. and KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC. As a result of the relationships described in footnotes (5) and (6), each of the Reporting Persons may be deemed to have beneficial ownership of the securities held in one or more of the client accounts.